CN1879894A - Method for establishing anti-hepatitis C virus drug screening experimental animal model - Google Patents
Method for establishing anti-hepatitis C virus drug screening experimental animal model Download PDFInfo
- Publication number
- CN1879894A CN1879894A CN 200610076888 CN200610076888A CN1879894A CN 1879894 A CN1879894 A CN 1879894A CN 200610076888 CN200610076888 CN 200610076888 CN 200610076888 A CN200610076888 A CN 200610076888A CN 1879894 A CN1879894 A CN 1879894A
- Authority
- CN
- China
- Prior art keywords
- virus
- hepatitis
- hcv
- infection
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to a method for selecting anti-hepatitis C medicine, which injects the artifical hepatitis C virus into tree mouse with negative hepatitis C, to build the hepatitis C natural infection model; via following steps as (1) composing hepatitis C virus; (2) injecting it into normal tree mouse, while the virus carried amount of each animal is higher than 105c; (3) fixing the hepatitis C virus naturally to infect the tree mouse model; (40 using the mouse model with positive hepatitis C virus to select the anti- hepatitis C medicine.
Description
Technical field
The present invention relates to the hepatitis C virus field.Specifically, the present invention relates to a kind of method and experimental animal model of setting up anti-hepatitis C virus drug screening.
Background technology
The whole world has 1.7 hundred million people to infect hepatitis C virus (HCV) (Alter M, 1997) approximately.Nearly 2% at the infection rate of developed country, the HCV natural infection rate of China is about 2-3%, belongs to the high infected area of HCV (Wen Yumei, 1999).Acute hepatitis C patients 70-80 can develop into chronic hepatitis, and wherein 5-10 can develop into liver cirrhosis and hepatocarcinoma (gold is strange, 2001).Since clone and separate HCV such as Choo success in 1989, the molecular biology research of HCV has been obtained bigger progress.Known so far HCV has 6 genotype, more than 30 kind of hypotype.But because high efficiency cell culture system is not also determined, lacked to the cell receptor of HCV fully, there is not appropriate H CV animal models infected, seriously hindered our understanding, the vaccine research of HCV and the research of specificity antivirus medicine walked with difficulty viral life cycle.Up to the present chimpanzee is the most desirable animal model of HCV infection, and the mode of its HCV infection, incidence type, pathological lesion and immunology change all with human quite similar.But endangered animal, the bodily form are big because chimpanzee belongs to, experiment and maintenance cost are very expensive, have limited its application in HCV research.
Tree shrew (tree shrew) (Tupaia belangeri) is that a kind of bodily form is little, breeding is fast, be easy to raise, be distributed widely in China west and south and Southeast Asia one band, the mammal between Insectivora and Primates on the taxonomy.Existing report tree is to multiple medical science virus susceptible, as hepatitis A virus (HAV) (Zhan Meiyun etc., 1981), hepatitis B virus (Yan Ruiqi etc., 1984; Eike Walter et al, 1996), hepatitis D virus (Li Qifen etc., nineteen ninety-five, 1996), rotavirus (Wan Xinbang etc., nineteen eighty-two, 1985), herpesvirus and datum hole Kenya virus (Zhang Hailin etc.,, 1997 years in 1992; Daral C, et al, 1980) etc.Domestic report (king sea equality, 1997 that tree shrew energy HCV infection was once arranged; Liu Zhi etc., 1998; Xie (Xie Zhichun) et al, 1998; Zhao et al, 2002).But because research uses viral source in the patients serum, virus concentration is not high, moreover does not have effective and feasible viral dense Su Fangfa and technology, and the model success rate of foundation is low, and genotype is simple, can't satisfy the antiviral drugs screening to the experimental model needs.
Summary of the invention
The purpose of this invention is to provide a kind of method of new screening anti-hepatitis c virus medicine, set up hepatitis C natural infection model.
Another object of the present invention is that the animal model that utilizes said method to set up carries out the screening of anti-hepatitis c virus medicine.
The present invention relates to a kind of method of screening the anti-hepatitis c virus medicine, it comprises the steps:
(1) male, the hepatitis C virus virus load that used placebo of vitro detection infection with hepatitis C virus is 10
5C-10
9HCV virus load in the serum of c;
(2) the HCV virus load in the serum of male, the tree shrew of having used screened medicine of vitro detection infection with hepatitis C virus;
(3) variation of HCV virus load in comparison step (1) and (2).
In the said method, the male tree shrew of infection with hepatitis C virus is preferably by the infection with hepatitis C virus of synthetic.And more preferably described synthetic hepatitis C virus comprises genotype 1a or 1b.
In the said method, the male tree shrew virus load of described infection with hepatitis C virus is greater than 10
5C, and preferred virus carrying capacity 10
5C-10
9C.
More particularly, the present invention relates to a kind of method of screening the anti-hepatitis c virus medicine, it is characterized in that, the hepatitis C virus of synthetic is injected in the tree shrew body of hepatitis C virus feminine gender, set up tree shrew hepatitis C natural infection model, screen the anti-hepatitis c virus medicine by following four steps:
(1). the worker synthesizes hepatitis C virus;
(2). the hepatitis C virus of synthetic is injected in the normal tree shrew body, and every internal animal virus carrying capacity is greater than 10
5C;
(3). confirm the positive tree shrew model of type C hepatitis virus natural infestation;
(4). by the anti-screening of hepatitis c virus-positive tree shrew model discrimination anti-hepatitis c virus medicine.
In the present invention, the hepatitis C virus of synthetic comprises 6 genotype, as 1a, and 1b.
The hepatitis C virus that the present invention further discloses synthetic is by the liposome transfection method pHCV of total length to be transfected into mammalian cell, adds the poxvirus that contains the T7 promoter, cultivates 24-48 hour for 35-37 ℃, and centrifugal collection supernatant obtains.The method of synthetic hepatitis C virus has a detailed description and introduces in granted patent 01114678.8.The virus load of synthetic is greater than 10
9C is far longer than serum virus extracted amount 10
4C.
It is intravital among the present invention the hepatitis C virus of synthetic to be injected into tree shrew by variable concentrations, and the third type pneumonitis virus content of every animal is 10
5C to 10
9Between the c, preferential 10
5C to 10
8C, override 10
6C to 10
7Between the c.
The hepatitis C animal model that the present invention sets up can be by the natural process of anthropomorphic dummy's infection with hepatitis C virus, in the application of the natural infection process that is used for studying hepatitis C virus.Also can be applicable in the anti-hepatitis C medicine of screening.
The present invention compared with prior art has following distinguishing feature:
1, hepatitis C virus model success rate height.Because rational virus inoculation amount, the model success rate reaches more than 90%.
2, can establish genotype animal model targetedly, as hepatitis C virus 1a genotype, or hepatitis C virus mixes the genotype animal model.
3, the 3 animal bodily forms are little, and are easy to obtain, and experiment and maintenance cost reduce, and enlarge its application in HCV research.
Description of drawings
Accompanying drawing 1 is an ALT change curve behind the virus inoculation body of the present invention;
Accompanying drawing 2 is liver HCV-RNA RT-PCR detection figure;
Accompanying drawing 3 is SABC with core is one anti-, core, * 400 figure as a result;
Accompanying drawing 4 is SABC with NS5A is one anti-, NS5A, * 400 figure as a result;
Accompanying drawing 5 is SABC with NS3-NS4 is one anti-, NS3-NS4, * 400 figure as a result;
Accompanying drawing 6 is SABC with E2 is one anti-, E2, * 400 figure as a result.
Specific embodiment
Below in conjunction with accompanying drawing and specific embodiment, further illustrate the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.
The synthetic of embodiment 1, hepatitis C virus and quantitative
1. hepatitis C virus is synthetic
With the carrier pHCV-2 (CCTCC M201013) that patent 200311111111 obtains, get 1 μ g ScaI enzyme action and cross pHCV-2 and add among the 100 microlitre OPTI-MEM, get 1 μ g pHCV-2 and added the mid-room temperature of 100 microlitre OPTI-MEM 15 minutes; And get 5 microlitre LF2000 and add 15 minutes mixings of the mid-room temperature of 95 microlitre OPTI-MEM, with carrier and LF2000 mixing, transfection 10
5Individual Hela cell, and establish carrier-free and two matched groups of no LF2000, after 6 hours transfection, remove transfection medium, and replace with the DMEM that contains 2.5% hyclone, contain 10 in the DMEM culture medium
7Pfu vTF7-3 (ATCC N0 VR-2153) recombinant poxvirus, and add 10 milligrams/every milliliter of rifampicin.After 2 hours inoculation, remove inoculum, cell is cultivated in the DMEM that contains 2.5% hyclone.Behind 48-72 hour incubation, collect the cell culture supernatant liquid that contains hepatitis C virion.
2. measure the titre of amplicon virus with RT-PCR
In 24 orifice plates, add Huh 7 cells, every hole 10
6Individual cell after 24 hours, removes supernatant, adds the cell culture supernatant night that 5. embodiment obtains, 10 times of dilutions of this supernatant, the supernatant after the dilution of every hole adding 1ml.After 24 hours, remove inoculum, and replace it with the fresh DDMEM of the 1ml that contains 10% hyclone.After cultivating 2 days, collecting cell, and from cell, extract whole RNA.With the electrophoresis band of RT-PCR detection hepatitis C virus, the PCR primer sequence is: the RT-PCR primer is SEQ ID NO:14, and the PCR primer is SEQ ID NO:15 and SEQ ID NO:116.Every hole adds 800 microlitre Trizol Reagent, and piping and druming makes the abundant cracking of cell repeatedly, and places 5 minutes in room temperature; Add 160 microlitre chloroforms, shook the EP pipe 15 seconds, room temperature was placed 2-3 minute; In 4 ℃, 12000 left the heart 15 minutes, abandoned supernatant; Add 400 microlitre isopropyl alcohols, room temperature was placed 10 minutes, left the heart 10 minutes in 4 ℃ 12000, abandoned supernatant; Add 75% ethanol, 800 microlitre precipitated rnas, and in 4 ℃, 7500 left the heart 5 minutes; Abandon supernatant, the RNA air drying of heavy collection, it is standby to add 20-40 μ l sterilized water dissolving RNA.RNA reverse transcription cumulative volume 30 μ l, reaction system is as follows: RNA 15 microlitres, primer 1 microlitre, 75 ℃ of degeneration minute are put-3 ℃, 3 minutes; Add 5x buffer 6 microlitres, dNTP 6 microlitres, Rnasin 1 microlitre, cumulative volume 29 microlitres stopped 2 minutes at 42 ℃, added MMLVRTase, 1 microlitre, 37 ℃ stopped 50 minutes, and 70 ℃ of deactivations in 15 minutes obtain hepatitis C virus cDNA.The pcr amplification reaction system is Buffer 5 microlitres, cDNA 2 microlitres, MgCl
24 microlitres, dNTP 4 microlitres, each 1 microlitre of upstream and downstream primer, Taq enzyme 0.5 microlitre, distilled water 36.5 microlitres; The PCR reaction condition be 95 ℃ 1 minute, 95 ℃ 30 seconds-56 ℃ 30 seconds-72 ℃ 40 seconds-72 ℃ 5 minutes, Tn32 circulation.Amplified production is in-20 ℃ of storages.
Deposition condition 2% agarose, 18V/ centimetre of voltage, electrophoresis 10-15 minute, visible 300bp band was the hepatitis C virus electrophoresis band.
3. detect the titre of amplicon virus with the RT-PCRR fluorescent quantitation
Operate according to the peaceful thing of Shenzhen Da Er Engineering Co., Ltd's product hepatitis C virus nucleic acid amplification (PCR) fluorescence detection reagent kit description.Testing result is judged: calculate Ax=A
1-A
0(A
0For reacting preceding value, A
1For reacting the back value); The experiment distinguishing validity is called N with the Ax of negative control pipe, and the Ax value of critical positive criteria product is called P1, and strong positive standard value Ax is called P2, if this 3 value satisfies P2＞P1＞N, then this experiment effectively.Otherwise it is invalid to test, and should check the error of aspects such as reagent, instrument, reaction condition.The result judges that under the effective prerequisite of experiment, sample Ax＞N+0.6 * (P1-N) judgement is positive; If N+0.6 * (P1-N)＞Ax＞N+0.4 * (P1-N) then belong to the experiment gray area needs repeated experiments once, if repeated experiments as a result Ax value＞N+0.4 * (P1-N) be judged to the positive, otherwise be judged to the positive; If Ax were value＜N+0.4 * (P1-N) would be judged to feminine gender.
RT-PCR fluorescent quantitation testing result
| Numbering | Embodiment | (the HCV gene is examined shellfish number/ml) to the transfection HeLa cell supernatant | (the HCV gene is examined shellfish number/m1) to infect the Huh-7 cell pyrolysis liquid |
| 1 | ⑤ | 7.0×10 10 | 4.4×10 9 |
| 2 | ⑥ | 8.0×10 9 | 3.2×10 8 |
| 3 | ⑦ | 6.8×10 8 | 2.8×10 8 |
| 4 | The vTF7-3 contrast | Negative | Negative |
| 5 | The normal cell contrast | Negative | Negative |
The foundation of embodiment 2, animal model and affirmation:
Extract animal blood, PCR method detects hepatitis C virus in the animal body, the hepatitis C of examination animal.All laboratory animals are before the hepatitis C virus of inoculation synthetic, and PCR detects and is negative.The virus of synthetic is from tail intravenous inoculation 0.8ml, second day the 3rd day lumbar injection 0.6ml more respectively, and inoculum concentration is 2ml, the virus load of every animal is 10
5More than the c, be divided into 7 groups.The virus load difference, the success rate difference of the positive model in inoculation back, every animal inoculation virus load comprises 10 at 104c
4C, the success rate of setting up the hepatitis C virus animal model is below 34%.Every animal inoculation virus load is 10
9C comprises 10
9C, the success rate of setting up the hepatitis C virus animal model is more than 86%, but the mortality rate of animal is also high, reaches more than 15%.Preferential 10
5C to 10
8C, override 10
6C to 10
7Between the c.
The animal positive is confirmed in the following manner:
1. the recombinant HCV viral infection is set HCV RNA detection case:
| Cycle | S2 |
| The 8th week of the 5th week the 3rd week second week first week | - +++ - - - |
2. ALT change curve behind the virus inoculation body is seen accompanying drawing 1.
3. liver HCV-RNA RT-PCR detects, and sees accompanying drawing 2.
HCV in-vitro multiplication system viral infection tree, liver HCV-RNA RT-PCR testing result:
1.100bp DNA Ladder Marker(TAKARA)；
2.pHCV；
3.S1；
4.S2；
5.S7；
6.S8；
7.S10；
8.S13；
9.S14；
10.pHCV transfection Hela supernatant;
(11.D1 control animals);
(12.D2 control animals);
13. blank (add amplimer in the PCR reaction system, do not add template);
14.100bp DNA Ladder Marker(TAKARA)；
S1, S2, S7, S8 are pHCV transfection Hela supernatant infected group;
S10 is 2 subinfection HCV (pHCV transfection Hela supernatant infects Huh-7) infected group;
S13, patient's S14HCV blood plasma infected group (the positive infection contrasts).
4. SABC result
4.1 with core is one anti-, core, and * 400, see accompanying drawing 3;
4.2 with NS5A is one anti-, NS5A, and * 400, see accompanying drawing 4;
4.3 with NS3-NS4 is one anti-, NS3-NS4, and * 400, see accompanying drawing 5;
4.4 with E2 is one anti-, E2, and * 400, see accompanying drawing 6;
Confirm the positive tree shrew model of type C hepatitis virus natural infestation.
Embodiment 3, the anti-screening of hepatitis c virus-positive tree shrew model discrimination anti-hepatitis c virus medicine.
Select successfully infected animals (RT-PCR, the SABC positive) 40 are divided into A at random, two groups of B, every group 10 are extracted blood testing HCV virus load placebo (normal saline) respectively, PEG IFN-α-2a (Roche), PEG IFN-α-2bRoche), ribavirin ribavirin, RBV Roche) administration, dosage is pressed the weekly RBV of 1.0 μ g/kg SQ (subcutaneous injection) of the weekly PEG IFN-α of PEG IFN-α-2a 1.5 μ g/kgSQ (subcutaneous injection)-2bRoche), body weight is oral less than 150g2mg every day 2 times, body weight greater than behind 150g 3mg every day 2 oral administrations respectively at 1,2,4,8 weeks were extracted blood test HCV virus load.
10 animals of A group, 8 all inner virus carrying capacity change
| 1 week | 2 weeks | 4 weeks | 8 weeks | |
| A1 | 1.37×10 3 | 1.10×10 3 | 8.30×10 2 | 8.95×10 2 |
| A2 | 2.46×10 4 | 7.39×10 4 | 2.30×10 4 | 9.27×10 3 |
| A3 | 1.98×10 3 | 7.54×10 3 | 4.98×10 3 | 9.50×10 2 |
| A4 | 5.42×10 5 | 2.01×10 5 | 3.69×10 5 | 6.38×10 5 |
| A5 | 8.21×10 4 | 1.77×10 5 | 1.05×10 5 | 2.14×10 5 |
| A6 | 5.40×10 3 | 4.61×10 3 | 7.55×10 3 | 7.39×10 3 |
| A7 | 3.50×10 3 | 1.05×10 3 | 8.79×10 2 | 7.34×10 2 |
| A8 | 1.06×10 5 | 4.50×10 5 | 2.07×10 5 | 9.78×10 4 |
| A9 | 7.90×10 3 | 4.44×10 3 | 1.98×10 3 | 9.85×10 2 |
| A10 | 9.15×10 4 | 8.33×10 4 | 9.36×10 4 | 7.11×10 4 |
B organizes 10 animals, 8 all inner virus carrying capacity and changes
| 1 week | 2 weeks | 4 weeks | 8 weeks | |
| B1 | 7.11×10 3 | 4.15×10 3 | 2.50×10 2 | 1.43×10 1 |
| B2 | 4.93×10 3 | 7.16×10 2 | 4.60×10 1 | Negative |
| B3 | 1.98×10 3 | 7.54×10 3 | 4.98×10 3 | 9.50×10 2 |
| B4 | 5.42×10 5 | 2.01×10 5 | 3.69×10 5 | 6.38×10 5 |
| B5 | 8.21×10 4 | 1.77×10 5 | 1.05×l0 5 | 2.14×10 5 |
| B6 | 5.40×10 3 | 4.61×10 3 | 7.55×10 3 | 7.39×10 3 |
| B7 | 3.50×10 3 | 1.05×10 3 | 8.79×10 2 | 7.34×10 2 |
| B8 | 1.06×10 5 | 4.50×10 5 | 2.07×10 5 | 9.78×10 4 |
| B9 | 7.90×10 3 | 4.44×10 3 | 1.98×10 3 | 9.85×10 2 |
| B10 | 9.15×10 4 | 8.33×10 4 | 9.36×10 4 | 7.11×10 4 |
Claims (5)
1. method of screening the anti-hepatitis c virus medicine, it comprises the steps:
(1) male, the hepatitis C virus virus load that used placebo of vitro detection infection with hepatitis C virus is 10
5C-10
9HCV virus load in the serum of c;
(2) the HCV virus load in the serum of male, the tree shrew of having used screened medicine of vitro detection infection with hepatitis C virus;
(3) variation of HCV virus load in comparison step (1) and (2).
2. the described method of claim 1, wherein the male tree shrew of infection with hepatitis C virus is by the infection with hepatitis C virus of synthetic.
3. the described method of claim 2, wherein said synthetic hepatitis C virus comprises genotype 1a or 1b.
4. claim 1,2 or 3 described methods, the virus load of the male tree shrew of wherein said infection with hepatitis C virus is greater than 10
5C-10
9C.
5. the described method of claim 5, the virus load of the male tree shrew of wherein said infection with hepatitis C virus is 10
5C-10
9C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100768882A CN100371022C (en) | 2006-05-10 | 2006-05-10 | Method for establishing anti-hepatitis C virus drug screening experimental animal model |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100768882A CN100371022C (en) | 2006-05-10 | 2006-05-10 | Method for establishing anti-hepatitis C virus drug screening experimental animal model |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1879894A true CN1879894A (en) | 2006-12-20 |
| CN100371022C CN100371022C (en) | 2008-02-27 |
Family
ID=37518391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100768882A Expired - Fee Related CN100371022C (en) | 2006-05-10 | 2006-05-10 | Method for establishing anti-hepatitis C virus drug screening experimental animal model |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100371022C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102818878A (en) * | 2012-06-18 | 2012-12-12 | 辉源生物科技（上海）有限公司 | Method for screening GHSR1a agonist drug |
| CN106047870A (en) * | 2016-06-16 | 2016-10-26 | 中国医学科学院医学生物学研究所 | Tupaia belangeri MHC-DRB1*1101 gene sequence and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2313739C (en) * | 1999-07-16 | 2011-11-22 | Enzo Therapeutics, Inc. | Model animals of human retrovirus infection |
| WO2002038793A2 (en) * | 2000-11-07 | 2002-05-16 | Anadys Pharmaceuticals, Inc. | Hepatitis c virus constructs characterized by high efficiency replication |
| CN1480911A (en) * | 2003-06-18 | 2004-03-10 | 张堰黎 | Building animal model of asthenopia based on tupaia belangeri as experiment animal |
-
2006
- 2006-05-10 CN CNB2006100768882A patent/CN100371022C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102818878A (en) * | 2012-06-18 | 2012-12-12 | 辉源生物科技（上海）有限公司 | Method for screening GHSR1a agonist drug |
| CN102818878B (en) * | 2012-06-18 | 2014-11-26 | 辉源生物科技（上海）有限公司 | Method for screening GHSR1a agonist drug |
| CN106047870A (en) * | 2016-06-16 | 2016-10-26 | 中国医学科学院医学生物学研究所 | Tupaia belangeri MHC-DRB1*1101 gene sequence and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100371022C (en) | 2008-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Askarieh et al. | Systemic and intrahepatic interferon‐gamma‐inducible protein 10 kDa predicts the first‐phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C | |
| CN106834290A (en) | A kind of circular rna and application thereof | |
| CN103458913A (en) | Treatment for infection with Hepatitis B virus alone or in combination with Hepatitis Delta virus and associated liver diseases | |
| CN101322847A (en) | Anti-hepatitis b virus gene medicament based on siRNA pool interference and mediated by complex carrier | |
| CN1059659A (en) | The diagnosis of viral hepatitis and treatment | |
| CN1879894A (en) | Method for establishing anti-hepatitis C virus drug screening experimental animal model | |
| CN104017806A (en) | MicroRNA (Ribose Nucleic Acid) and application thereof in preparation of active tuberculosis detection reagent | |
| Aly et al. | Strain‐dependent viral dynamics and virus‐cell interactions in a novel in vitro system supporting the life cycle of blood‐borne hepatitis C virus | |
| CN101298605A (en) | Hepatitis C virus in vitro replication model, construction method and use thereof | |
| JP5327793B2 (en) | Hepatitis virus propagation method and use thereof | |
| CN114246847B (en) | Application of chalcone compounds in treatment of coronavirus infection | |
| CN104257655B (en) | Compound MEAN purposes in the medicine that preparation suppresses HCV to replicate | |
| CN102517387B (en) | Application of MVP used as antiviral drug target | |
| Dash et al. | Transmission of HCV to a chimpanzee using virus particles produced in an RNA‐transfected HepG2 cell culture | |
| CN1276093C (en) | Method for detecting hepatitis c virus PdRP enzyme, carrier and cell strain transformed by same and application | |
| CN101058802A (en) | Cell system for indicating bovine foamy virus infection and application thereof | |
| CN101906417A (en) | shRNA for hepatitis B virus and recombinant adeno-associated virus vector treating vector carrying same | |
| CN104758282B (en) | Berberine is for preparing the purposes of the medicine of viral myocarditis disease caused by treatment Coxsackie B virus 3 | |
| Szabo et al. | GBV-C/HGV infection in renal dialysis and transplant patients. | |
| CN1274363C (en) | Auxiliary therapeutic agent for C type hepatitis | |
| Pan et al. | B lymphocyte-mediated humoral immunity in the pathogenesis of chronic hepatitis B infection | |
| Wu et al. | Research progress on the mechanism of persistent low-level HBsAg expression in the serum of patients with chronic HBV infection | |
| CN102888468B (en) | Detection method and kit for infectious muscle necrosis of penaeus vanmamei | |
| CN1468955A (en) | New type of coronavirus | |
| CN108324930A (en) | Interleukin-22 1（IL-21）Purposes in preparing hepatitis B virus resisting medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Li Weiyun Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice |
Addressee: Li Weiyun Document name: Notification of Termination of Patent Right |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080227 Termination date: 20140510 |
|
| EXPY | Termination of patent right or utility model |